Abstract 5850: Association Between Cardiac Magnetic Resonance Imaging (CMR) Parameters and Clinical Outcomes in Patients with Transthyretin Cardiac Amyloidosis on Disease Modifying Therapy
Abstract
Background: Cardiac magnetic resonance imaging (CMR) is instrumental in the early diagnosis of transthyretin cardiac amyloidosis (ATTR-CA), which may be particularly beneficial for early initiation of disease modifying therapies (DMT). Prior studies have demonstrated superior outcomes in patients who had early DMT initiation (NYHA I-II), preserved baseline cardiac function, and adequate renal function. The role of CMR, however, in predicting outcomes in patients on various DMT is less defined. Question: The objective of our study is to assess clinical and CMR predictors of outcomes in ATTR-CA patients on DMT. Methods: This single-center longitudinal follow-up cohort study includes adults with ATTR-CA receiving DMT (stabilizer and/or silencer). Only patients with a CMR obtained prior to starting therapy are included for analysis. Baseline demographic, clinical, and CMR parameters were obtained and are reported as summary statistics. Primary outcome was defined as a composite of all-cause mortality and heart failure (HF) hospitalization. Cox proportional hazard models were created to assess clinical and radiologic predictors of time to primary outcome. Results: The study cohort is comprised of 72 patients (mean age 78 ± 8.7 years, female 33.3%) with ATTR-CA on DMT. Distribution of type of DMT was 59.7% (n=43) on stabilizer alone, 4.2% (n=3) on silencer alone, and 36.1% (n=26) on both. Clinical and CMR characteristics are delineated in Table 1. Across a median follow up of 3.3 years, there were 7 (9.7%) deaths from any cause and 21 (29.2%) patients who were hospitalized for HF. In survival models, lower baseline ejection fraction (HR 0.95, p=0.010), chronic kidney disease (HR 2.57, p=0.025), diabetes (HR 2.58, p=0.031), and higher ECV on CMR (HR 1.07, p=0.050) were associated with the primary outcome. The type of DMT (e.g. stabilizer, silencer, or both) was not a predictor of outcomes. Other CMR parameters, including T1 time, scar burden, and LGE, were not associated with outcomes. Composite outcome by ECV is visualized via probability curve and Kaplan Meier survival curve in Figure 1. Conclusion: In this cohort, higher ECV was the only CMR parameter associated with worse outcomes in ATTR-CA patients on any type of DMT. Notably, LGE burden was not significantly associated with outcomes. These findings may be explained by the characteristically diffuse, non-focal fibrosis in ATTR-CA that would make a global marker like ECV more ideal in capturing disease severity. Additionally, outcomes did not change by type of DMT, suggesting that disease burden may be a stronger prognosticator than choice of therapeutic agent.